INTRODUCTION AND OBJECTIVES: Active surveillance (AS) has been showed to be feasible and effective in a sub-set of patients with recurrent low-grade non-muscle invasive bladder cancer (LG-NMIBC). Xpert BC Monitor is a new mRNA-marker test for BC followup, which measures the levels of five target mRNAs from a voided urine sample by real-time RT-PCR. The aim of this study was to test the hypothesis that Xpert Bladder monitor test may improve the diagnosis of failure and avoid unnecessary TURBT in patients under AS.
METHODS: This is a prospective observational cohort study of patients with a previous pathologically confirmed NMIBC, who experienced recurrence during follow-up and accepted to undergo AS according to the Bladder Cancer Italian Active Surveillance project (BIAS_ICH_V1.2_27.01.2018). in addition to urine cytology, urinary samples were analysed using Xpert BC Monitor (Cepheid, Sunnyvale, CA, USA) at each follow-up or at entry in case of a new episode of AS, measuring the gene expression levels of five targets (ABL1, CRH, IGF2, UPK1B, ANXA10) by RT-PCR according to the manufacturer's protocol. The primary end point was to compare Xpert BC Monitor results, with urine cytology, cystoscopy imaging and pathological assessment in case of active treatment (TURBT) for AS failure. Data were complemented by descriptive statistical analysis and the sensitivity, specificity, PPVs and NPVs were calculated.
RESULTS: Of 63 patients (mean age 73.3 yrs AE 9.6; male/female 45/18) who were tested with Xpert BC Monitor, 42 were positive, 19 negative and 2 tests resulted invalid. Forty-three patients were deemed to have malignant lesions and 18 patients were suspected benign according to cystoscopic imaging. No patient of the whole cohort had a positive urine cytology. Xpert BC Monitor was positive in 40 patients with malignant lesions and in 2 suspected benign patients (11.%), resulting in a sensitivity of 93% and a specificity of 89%. Twelve (19%) patients of these 63 patients required treatment because the lesions had grown or progressed. In this subset the sensitivity of Xpert BC Monitor was 91%. Forty-nine patients remained under AS. As two patients had invalid Xpert BC Monitor results, in the remaining 47 patients, Xpert BC Monitor had a sensitivity of 86.2% with a specificity of 72.2%, PPV of 83.3% and NPV of 76.4%.
CONCLUSIONS: Xpert BC Monitor correctly identified most patients in AS with LG malignant lesions and negative urine cytology. Negative Xpert BC monitor could avoid unnecessary TURBT and its combination with other tools might improve accuracy of decision making.
Source of Funding: None

PD18-06 PROSPECTIVE EVALUATION OF THE PREDICTIVE ROLE OF IMMEDIATE URINE CYTOLOGY (IUC) AFTER TRANSURETHRAL RESECTION OF NON-MUSCLE INVASIVE BLADDER CANCER
Amr Elsawy*, mansoura, Egypt; Fady Kamal, Ahmed Harraz, Bedeir Ali-El-Dein, Mansoura, Egypt INTRODUCTION AND OBJECTIVES: There is evidence that immediate urine cytology (IUC) after primary resection might predict clinical stage and early tumor recurrence. The aim of this work is to prospectively evaluate the value of immediate urine cytology after the primary TURBT of NMIBC.
METHODS: After approval of institutional review board (IRB), patients undergoing TURBT for T1 NMIBC between February 2015 and June 2016, were included in the study. Patients with concomitant CIS, upper tract urothelial tumors, biopsy proven muscle invasion, or for whom second resection was done were excluded. Forty-eight hours after TURBT, IUC was retrieved and patients were scheduled for second look cystoscopy four weeks later. The primary outcome was to determine the predictive role of positive IUC on positive biopsy for malignancy at time of second look cystoscopy.
RESULTS: During the study period, 70 patients including 60 males and 10 females fulfilled the study inclusion criteria of which 17 (24.3%) patients had history of TURBT for NMIBC. During cystoscopy, tumors were single, 2-7, and >7 in 40 (57.1%), 29 (41.4%), and 1 (1.4%) patients, respectively. The mean (SD) largest bladder lesion size was 26 (9) mm. The histopathology revealed T1 stage in all patients. High grade malignancy was encountered in 9 (12.6%) patients. The EORTC risk of recurrence was intermediate in all patients while the risk of progression was intermediate and high in 19 (27.1%) and 51 (72.9%) patients, respectively. The median (IQR) EORTC recurrence and progression risk scores were 5 (2) and 9 (3), respectively. The results of IUC were low grade malignance in 31 (44.3%) patients, high grade malignancy in 7 (10%), inflammatory in 27 (38.6%), and hyperplastic in 5 (7.1%).The second-look cystoscopy was performed after a mean (SD) of 36 (15) days.The histopathological findings in the second look were cystitis and non-muscle invasive urothelial tumor in 41 (58.6%) and 29 (41.4%) patients, respectively. Among patients with positive IUC, 26 (68.4%) patients were diagnosed with urothelial carcinoma at second look cystoscopy compared to 3 (9.4%) patients with negative IUC (p < 0.001). The sensitivity and specificity of IUC were 89.6% and 70.7%, respectively. The positive predictive and negative predictive values were 64.4% and 90.6%, respectively.
CONCLUSIONS: Immediate urine cytology after TURBT for intermediate recurrence risk NMIBC is significantly associated with positive second-look TURBT for malignancy. The sensitivity and negative predictive value were 89.6% and 90.6%, respectively. IUC can be done routinely after TURBT to help planning of further intervention.
Source of Funding: None.
PD18-07 A NON-INVASIVE URINE-BASED METHYLATION BIOMARKER PANEL FOR BLADDER CANCER DETECTION
INTRODUCTION AND OBJECTIVES: Aberrant DNA methylation is very common in bladder cancer (BC) pathogenesis and progression. These epigenetic alterations are detectable in voided urine and might be useful as non-invasive urinary biomarkers for the early detection of BC. We aimed to assess whether a panel of previously identified differentially methylated genes can be used as diagnostic urine assay to predict the presence of BC and discriminate between low-grade (LG) and high-grade (HG) disease.
METHODS: Urinary DNA was extracted from voided urine of 313 patients with LG or HG BC and BC-free controls in 4 different centers (Toronto (2) and Halifax, CA and Zurich, CH). Methylation status of urinary cell sediment DNA was evaluated using qPCRbased MethyLight assay for 5 different genes (TWIST1, RUNX3, GATA4, NID2, FOXE1). These genes were previously identified to be
